Cardiovascular Function in COPD Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-29

Study Completion Date

2018-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of the study are to explore the effect of treatment with tiotropium + olodaterol fixed dose combination (FDC) compared to fluticasone propionate + salmeterol FDC on:

* reversal of left ventricular diastolic dysfunction assessed with cardiac magnetic resonance (CMR) imaging,
* measures of arterial stiffness assessed by CMR and pulse wave analysis (PWA),
* reduction of hyperinflation assessed with body plethysmography and
* post dose spirometry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

NCT02030535

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

NCT01969721

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD

NCT02683109

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

NCT00530842

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

NCT00578968

Chronic Obstructive Pulmonary Disease COPD

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tiotropium/Olodaterol Fixed Dose Combination

Group Type EXPERIMENTAL

Tiotropium

Intervention Type DRUG

Fixed Dose Combination

Olodaterol

Intervention Type DRUG

Fixed Dose Combination

Fluticasone Propionate + Salmeterol Fixed Dose Combination

Group Type ACTIVE_COMPARATOR

Fluticasone propionate

Intervention Type DRUG

Fixed Dose Combination

Salmeterol

Intervention Type DRUG

Fixed Dose Combination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tiotropium

Fixed Dose Combination

Intervention Type DRUG

Olodaterol

Fixed Dose Combination

Intervention Type DRUG

Fluticasone propionate

Fixed Dose Combination

Intervention Type DRUG

Salmeterol

Fixed Dose Combination

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

INSPIOLTO, SPIOLTO, STIOLTO, VAHELVA, YANIMO INSPIOLTO, SPIOLTO, STIOLTO, VAHELVA, YANIMO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients must sign an informed consent consistent with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
* All patients must have a diagnosis of chronic obstructive pulmonary disease for which they are treated with one or more long-acting inhaled bronchodilators prior to enrolment and must meet the following spirometric criteria:

Patients must have stable airway obstruction with a post-bronchodilator Forced Expiratory Volume in 1st second (FEV1) \< 70% of predicted normal calculated with European Coal and Steel Community (ECSC) formulas, and a post-bronchodilator FEV1/Forced Vital Capacity (FVC)\< 70% at Visit 1

* Patients with hyperinflation at rest defined as Functional Residual capacity (FRC) \> 120 % predicted, with post-bronchodilator reversibility greater than and equal to 7,5 % predicted at Visit 1.
* Male or female patients between 40 and 75 years of age (inclusive) on day of signing informed consent.
* Patients with a smoking history of more than 10 pack years.
* Patients with Modified Medical Research Council (mMRC) Dyspnoea score \> 1 at Visit 1.
* Patients must be able to perform technically acceptable pulmonary function tests (spirometry and body plethysmography), Cardiac Magnetic Resonance (CMR), brachial blood pressure measurements with Pulse Wave Analysis (PWA) and other tests during the study period as required in the protocol.
* Patients must be able to inhale medication in a competent manner from the Respimat and Accuhaler inhalers and from a metered dose inhaler (MDI).

Exclusion Criteria

* Patients with a significant disease other than Chronic Obstructive Pulmonary Disease (COPD).
* Patients with a clinically relevant abnormal baseline haematology, blood chemistry, or creatinine.
* Patients with a diagnosis of asthma.
* Patients with a COPD exacerbation in the 6 weeks prior to screening (Visit 1) and patients who experience COPD exacerbation or respiratory tract infection during the washout phase prior to randomisation.
* A history of myocardial infarction, cerebrovascular event or coronary artery intervention other than Coronary Artery Bypass Graft (CABG) within 1 year of screening.
* Abnormal and clinically significant 12-lead Electrocardiogram (ECG).
* Hospitalized for heart failure within the past year. Current severe heart failure (New York Heart Association (NYHA) class IV. Ejection fraction \<= 40% from Cardiac Magnetic Resonance (CMR) baseline assessment.
* Patients with systolic blood pressure \> 140mmHg and/or diastolic blood pressure \> 90mmHg at Visit 1.
* A diagnosis of thyrotoxicosis.
* Known active tuberculosis, cardiac sarcoidosis.
* Any malignancy unless free of disease for at least five years.
* A history of cystic fibrosis.
* Clinically evident bronchiectasis.
* Patients with severe emphysema requiring endobronchial interventions within 6 months prior to screening.
* A history of significant alcohol or drug abuse.
* Patients who have undergone thoracotomy with pulmonary resection.
* Patients being treated with any oral ß-adrenergics.
* Patients being treated with oral corticosteroid medication within 6 weeks prior to Visit 1.
* Patients being prescribed long-term home oxygen treatment.
* Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
* Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit.
* Patients with known hypersensitivity to ß-adrenergics drugs, anticholinergic drugs, fluticasone propionate or to any of the excipients, Benzalkonium chloride (BAC), Disodium edentate (EDTA) or Lactose monohydrate (which contains milk proteins) or any other component of the Respimat® or Accuhaler® delivery systems.
* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
* Women of childbearing potential not using highly effective methods of birth control.
* Patients who have previously been enrolled in this study or are currently enrolled in another study.
* Patient who are unable to comply with pulmonary medication restrictions prior to randomisation
* Patients with pacemakers and metal implants (i.e. vascular clips and stents, metal silver in patient's eye) and patients with claustrophobia, due to contraindications for CMR.

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No